Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ASP Isotopes's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ASP Isotopes's regulatory disclosures and financial reporting.
ASP Isotopes Inc. outlined a proposed merger in which its wholly owned subsidiary Noble Africa LLC would combine with a subsidiary of ENDRA Life Sciences, with Noble Africa as the surviving entity. The combined company plans to be named Noble Africa Inc. and apply to list on Nasdaq under the ticker “NOBA.”
Alongside the merger, Noble Africa has secured commitments for a private placement expected to generate approximately $50 million in gross proceeds, including about $20 million from ASP Isotopes as lead investor and about $30 million from other investors, with $750,000 from certain ASP Isotopes directors and management. At closing, ASP Isotopes is expected to own about 89% of the combined company, pre-closing ENDRA stockholders about 3%, and other private placement investors about 7%, with closing targeted for the third or fourth quarter of 2026, subject to regulatory and stockholder approvals and other customary conditions.
ASP Isotopes Inc. announced that Tetra4, the Renergen subsidiary developing the Virginia Gas Project in South Africa, has signed its first five-year take-or-pay contract to sell liquid helium to an Asian industrial gases company at an initial base price above $600/MCF. The agreement covers about 15% of expected Phase 1 helium capacity and helps underpin multi-year cash flow ahead of targeted commercial production in the third quarter of 2026. Phase 1 is planned to produce roughly 70 MCF/day of liquid helium and 2,500 GJ/day of LNG, with Phase 2 targeted at about 900 MCF/day of helium and 34,000 GJ/day of LNG, supported by conditional approval for up to $750 million in senior debt financing.
ASP Isotopes Inc. COO Robert Ainscow reported selling 8,438 shares of common stock in open-market transactions at a weighted average price of $6.999 per share. According to the disclosure, these "sell to cover" trades were made under a Rule 10b5-1 trading plan adopted on June 9, 2025 to cover tax withholding obligations tied to vesting restricted stock awards, rather than discretionary sales. Following the transactions, Ainscow directly holds 2,281,879 ASP Isotopes shares.
ASP Isotopes Inc. filed a Rule 144 notice regarding proposed sales of Common Stock, listing 300,000 shares issued as a restricted stock award on 09/06/2024.
The filing also records an actual sale of 22,500 shares on 04/16/2026 for $117,112.50. The securities are registered for resale and were acquired as compensation.
ASP Isotopes Inc. Chairman and CEO Paul Elliot Mann reported both share sales and a new equity award. He sold a total of 251,275 shares of common stock in three open-market transactions at weighted average prices of $7.76, $7.88, and $8.29 per share. According to the disclosure, these were "sell to cover" trades under a Rule 10b5-1 plan to cover tax withholding on quarterly vesting of a restricted stock award. Mann also received a grant of 2,233,555 shares of common stock under his employment agreement, which will vest in four equal installments over a one-year period beginning on March 1, 2026.
Ainscow Robert reported acquisition or exercise transactions in this Form 4 filing.
ASP Isotopes Inc. Chief Operating Officer Robert Ainscow received an equity grant of 800,000 shares of common stock, awarded at a stated price of $0.0000 per share as compensation. Following this grant, he directly holds 2,290,317 common shares. The award will vest in semi-annual installments over four years, subject to applicable vesting conditions.
Ainscow Donald George reported acquisition or exercise transactions in this Form 4 filing.
ASP Isotopes Inc. executive vice president and general counsel Donald George Ainscow received an award of 400,000 shares of common stock as compensation. The filing shows he now holds 900,000 common shares directly. The award will vest in semi-annual installments over four years, subject to applicable vesting conditions beginning on the grant date.
ASP Isotopes Inc. reported that Chief Financial Officer Heather Kiessling acquired 840,000 shares of common stock through a stock award with a grant price of $0.0000 per share. Following this award, she holds a total of 1,549,376 common shares directly.
The award will vest in semi-annual installments over a four-year period, subject to applicable vesting conditions, meaning the shares are earned gradually over time rather than all at once.
Independent Trading Group (ITG) Inc. reported a Form 144 notice showing insider selling activity and recent equity compensation. The filing lists a sale of $881,463.71 for 162,153 shares reported on 03/02/2026. It also shows 2,233,555 restricted shares acquired as compensation on 05/28/2026. Shares outstanding are stated as 125,903,447 as of 06/01/2026.
ASP Isotopes Inc. reported operational progress at its Silicon-28 enrichment facility in Pretoria, South Africa. The company has successfully restarted the first 18 stages of the plant after nine months of engineering enhancements to non-core components such as valves, compressors, and piping, and these stages have operated for over three weeks at target enrichment levels.
The company has signed three commercial contracts to supply enriched Silicon-28 to U.S.-based customers and expects initial commercial shipments to begin in Q3 2026. Earlier, it shipped first samples in August 2025, with independent analysis confirming enrichment performance. The release highlights Silicon-28’s potential importance for quantum computing and next-generation semiconductors.